Occam Recruits Laurent Fischer as Chair of Shinobi Therapeutics
In November 2025, Occam Global, a leader in executive recruiting for the life sciences, placed Laurent Fischer, MD, as the first independent Chairman of the Board of Directors of Shinobi Therapeutics.
Fischer brings over 30 years of senior leadership experience in biotechnology to Shinobi, with a proven track record of building, growing, and exiting companies focused on innovative therapies. His achievements include selling Jennerex Biotherapeutics to SillaJen, leading Tobira Therapeutics through its IPO and its $1.7 billion acquisition by Allergan, chairing CTI BioPharma during the approval and launch of Vonjo™, and its subsequent $1.7 billion sale to SOBI, and most recently, selling Adverum Biotechnologies to Eli Lilly in October 2025.
Fischer also brings extensive board experience, including current positions as the first independent Director of Lycia Therapeutics, Director of Mirum Pharmaceuticals, and Director of AtaiBeckley. He previously served as Chair of Tobira Therapeutics, Chairman of CTI BioPharma, Director of Senti Biosciences, and Senior Advisor of Frazier Healthcare Partners.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.